Aidan Hollis

Learn More
This paper offers an economic rationale for compulsory licensing of needed medicines in developing countries. The patent system is based on a trade-off between the "deadweight losses" caused by market power and the incentive to innovate created by increased profits from monopoly pricing during the period of the patent. However, markets for essential(More)
This paper uses pooled cross-section data on Canadian ethical drug sales to examine the effect of entry timing on sales of generic drugs. The data is for all drugs for which the first generic competitor entered during the years 1994-1997. It is found that the first generic entrant has a lasting competitive advantage: being first into the market appears to(More)
Parallel imports are genuine products imported without the authorization of the trademark or copyright owner in a country. Authorized dealers have employed trademark and copyright law to exclude parallel imports using claims of infringement. Our assertion is that trademark and copyright laws are inappropriate for enforcing restrictions against parallel(More)
Because pharmaceutical markets are dysfunctional, the patent system does not effectively stimulate drug research and development. Instead, it induces large amounts of research into drugs with little incremental therapeutic value, while providing inadequate incentives to innovate in really novel areas. At the same time, patents result in high prices which(More)
Synthetic biology (SynBio) has tremendous, transformative potential. Like other technologies, it can be used for good or ill. Currently, the structure of the allocation of potential benefits and risks is biased in favor of richer countries. The underlying problem is simple: most risks from SynBio are universal and affect both the rich and the poor with(More)
n engl j med 369;26 nejm.org december 26, 2013 2474 Medicare has options for alleviating the shifting of resources away from hospitals serving more disadvantaged patients. First, the payment criteria in HVBP could be altered to give more weight to quality improvement than to quality achievement. Second, instead of having all acute care hospitals compete(More)
  • Aidan Hollis
  • Journal of pharmacy & pharmaceutical sciences : a…
  • 2004
PURPOSE This article compares pharmaceutical prices paid by governments in the United States and Canada. METHODS The comparator prices are those of the Federal Supply Schedule and the Ontario Drug Benefit List, for frequently prescribed brand name medicines. RESULTS The price differential between Canadian and US prices is shown to be relatively small,(More)